meta:
  schema_version: '1.0'
  compatible_engine: cellswarm>=2.0
combination_id: pembro_paclitaxel
components:
- pembrolizumab
- paclitaxel
clinical_trial: KEYNOTE-355
indication: TNBC
interaction_model: bliss_independence
synergy_rules:
  CD8_T:
    synergy_factor: 1.3
    affected_parameters:
    - activation
    - exhaustion
    - cytotoxicity
    notes: ICD from paclitaxel enhances anti-PD-1 response
  Tumor:
    synergy_factor: 1.2
    affected_parameters:
    - apoptosis_susceptibility
    notes: Immune-mediated + direct cytotoxicity
  Treg:
    synergy_factor: 1.1
    affected_parameters:
    - suppressive_activity
  Macrophage:
    synergy_factor: 1.1
    affected_parameters:
    - polarization
  NK:
    synergy_factor: 1.1
    affected_parameters:
    - activation
  B_cell:
    synergy_factor: 1.0
    affected_parameters: []
toxicity_interaction:
  irAE_probability: 0.3
  dose_adjustment: 0.85
cancer_specific_modifiers:
  TNBC:
    efficacy_modifier: 1.2
    notes: KEYNOTE-355 PD-L1+ CPS>=10 OS benefit
  Melanoma:
    efficacy_modifier: 0.8
    notes: Not standard combination
  NSCLC:
    efficacy_modifier: 0.9
    notes: KEYNOTE-189 uses pembro+chemo
  CRC-MSI-H:
    efficacy_modifier: 0.7
    notes: ICI preferred alone
  CRC-MSS:
    efficacy_modifier: 0.3
    notes: Limited benefit
  Ovarian:
    efficacy_modifier: 0.6
    notes: Investigational
references:
- description: 'KEYNOTE-355: Pembro+chemo in TNBC. Cortes et al. NEJM 2022'
  pmid: '35857659'
  verified: true
